Sul048 S-4321, A NOVEL DUAL-CELL BIFUNCTIONAL PD-1:FCyRIIB SELECTIVE AGONIST ANTIBODY FOR THE TREATMENT OF IMMUNE-MEDIATED AND AUTOIMMUNE DISEASES, MAINTAINS PD-1 EXPRESSION, DOES NOT DEPLETE T CELLS AND ENHANCES INHIBITORY RECEPTOR EXPRESSION IN VIVO

Gastroenterology 2026

View at publisher
Authors: Julia Manasson, Michael Cianci, Joshua Vitlip, Stephen Lutz, Elliott Wittenberg, Allison Colthart, Samuel Perry, Chelsea R. Parker Harp, Jyothsna Visweswaraiah, Ryan Peckner, Alex Pellerin, Heather Vital
+4 more John Sundy, Nathan Higginson-Scott, Kevin L. Otipoby, Daniela Cipolletta
DOI: 10.1016/s0016-5085(26)06565-0
Cited by: 1

Fields of Study & Subjects

CAR-T cell therapy research Cancer Immunotherapy and Biomarkers T-cell and B-cell Immunology

Publication details

Journal / source
Gastroenterology
Publisher
Elsevier BV
Volume
170
Issue
6
Pages
S–2768
Publication date
1 May 2026
Language
EN